A Direct Comparison of Selective BH3-mimetics Reveals BCL-X, BCL-2 and MCL-1 As Promising Therapeutic Targets in Neuroblastoma

Overview

Journal Br J Cancer

Specialty Oncology

Date 2020 Mar 24

PMID 32203216

Citations 16

Authors

Annika Bierbrauer

Maureen Jacob

Meike Vogler

Simone Fulda

Affiliations

Soon will be listed here.

Abstract

Background: Despite advances in the treatment of neuroblastoma, patients with high-risk disease still have dismal survival prognosis. Neuroblastoma cells display elevated expression of the antiapoptotic BCL-2 proteins, suggesting that BH3-mimetics may be a promising treatment option. Here, we investigated the role of BCL-2, BCL-X and MCL-1 in neuroblastoma.

Methods: A panel of neuroblastoma cell lines and primary patient-derived cells were exposed to BH3-mimetics targeting BCL-2 (ABT-199), BCL-X (A1331852) or MCL-1 (S63845). In addition, protein expression and interaction patterns were analysed using Western blotting and immunoprecipitation.

Results: All tested BH3-mimetics were able to induce apoptosis in neuroblastoma cell lines, indicating that not only BCL-2 but also BCL-X and MCL-1 may be promising therapeutic targets. Primary patient-derived cells displayed highest sensitivity to A1331852, highlighting the important role of BCL-X in neuroblastoma. Further analysis into the molecular mechanisms of apoptosis revealed that A1331852 and S63845 displaced proapoptotic proteins like BIM and BAK from their antiapoptotic targets, subsequently leading to the activation of BAX and BAK and caspase-dependent apoptosis.

Conclusions: By using selective BH3-mimetics, this study demonstrates that BCL-2, BCL-X, and MCL-1 are all relevant therapeutic targets in neuroblastoma. A1331852 and S63845 induce rapid apoptosis that is initiated following a displacement of BAK from BCL-X or MCL-1, respectively.

Citing Articles

Osteosarcoma cells depend on MCL-1 for survival, and osteosarcoma metastases respond to MCL-1 antagonism plus regorafenib in vivo.

Ji Y, Harris M, Newton L, Harris T, Fairlie W, Lee E BMC Cancer. 2024; 24(1):1350.

PMID: 39497108 PMC: 11533409. DOI: 10.1186/s12885-024-13088-7.

Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours.

Seiboldt T, Zeiser C, Nguyen D, Celikyurekli S, Herter S, Najafi S Br J Cancer. 2024; 131(4):763-777.

PMID: 38942989 PMC: 11333474. DOI: 10.1038/s41416-024-02740-5.

Unlocking the Therapeutic Potential of BCL-2 Associated Protein Family: Exploring BCL-2 Inhibitors in Cancer Therapy.

Dakkak B, Taneera J, El-Huneidi W, Abu-Gharbieh E, Hamoudi R, Semreen M Biomol Ther (Seoul). 2024; 32(3):267-280.

PMID: 38589288 PMC: 11063480. DOI: 10.4062/biomolther.2023.149.

Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x/Bcl-w Inhibitors.

Peng Z, Gillissen B, Richter A, Sinnberg T, Schlaak M, Eberle J Int J Mol Sci. 2024; 25(6).

PMID: 38542429 PMC: 10970841. DOI: 10.3390/ijms25063453.

Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma.

Borankova K, Krchniakova M, Leck L, Kubistova A, Neradil J, Jansson P Cell Death Dis. 2023; 14(11):747.

PMID: 37973789 PMC: 10654511. DOI: 10.1038/s41419-023-06278-x.

References

Schulte J, Eggert A . Neuroblastoma. Crit Rev Oncog. 2015; 20(3-4):245-70. DOI: 10.1615/critrevoncog.2015014033. View

Park J, Bagatell R, London W, Maris J, Cohn S, Mattay K . Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer. 2012; 60(6):985-93. DOI: 10.1002/pbc.24433. View

Grobner S, Worst B, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva V . The landscape of genomic alterations across childhood cancers. Nature. 2018; 555(7696):321-327. DOI: 10.1038/nature25480. View

Schwab M, Alitalo K, Klempnauer K, Varmus H, Bishop J, Gilbert F . Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature. 1983; 305(5931):245-8. DOI: 10.1038/305245a0. View

Zimmerman K, Yancopoulos G, Collum R, Smith R, Kohl N, Denis K . Differential expression of myc family genes during murine development. Nature. 1986; 319(6056):780-3. DOI: 10.1038/319780a0. View

Huang M, Weiss W . Neuroblastoma and MYCN. Cold Spring Harb Perspect Med. 2013; 3(10):a014415. PMC: 3784814. DOI: 10.1101/cshperspect.a014415. View

Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, De Pontual L, Combaret V . Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008; 455(7215):967-70. DOI: 10.1038/nature07398. View

Chen L, Willis S, Wei A, Smith B, Fletcher J, Hinds M . Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005; 17(3):393-403. DOI: 10.1016/j.molcel.2004.12.030. View

George R, Sanda T, Hanna M, Frohling S, Luther 2nd W, Zhang J . Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008; 455(7215):975-8. PMC: 2587486. DOI: 10.1038/nature07397. View

10.

van Groningen T, Koster J, Valentijn L, Zwijnenburg D, Akogul N, Hasselt N . Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nat Genet. 2017; 49(8):1261-1266. DOI: 10.1038/ng.3899. View

11.

Teitz T, Wei T, Valentine M, Vanin E, Grenet J, Valentine V . Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med. 2000; 6(5):529-35. DOI: 10.1038/75007. View

12.

Borriello L, Seeger R, Asgharzadeh S, DeClerck Y . More than the genes, the tumor microenvironment in neuroblastoma. Cancer Lett. 2015; 380(1):304-14. PMC: 5558454. DOI: 10.1016/j.canlet.2015.11.017. View

13.

Ara T, Nakata R, Sheard M, Shimada H, Buettner R, Groshen S . Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma. Cancer Res. 2013; 73(13):3852-64. PMC: 3740971. DOI: 10.1158/0008-5472.CAN-12-2353. View

14.

Adams J, Cory S . The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007; 26(9):1324-37. PMC: 2930981. DOI: 10.1038/sj.onc.1210220. View

15.

Beroukhim R, Mermel C, Porter D, Wei G, Raychaudhuri S, Donovan J . The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463(7283):899-905. PMC: 2826709. DOI: 10.1038/nature08822. View

16.

Tsujimoto Y, Cossman J, Jaffe E, Croce C . Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985; 228(4706):1440-3. DOI: 10.1126/science.3874430. View

17.

Castle V, Heidelberger K, Bromberg J, Ou X, Dole M, Nunez G . Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am J Pathol. 1993; 143(6):1543-50. PMC: 1887263. View

18.

Reed J, MEISTER L, Tanaka S, Cuddy M, Yum S, Geyer C . Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res. 1991; 51(24):6529-38. View

19.

Dole M, Nunez G, Merchant A, Maybaum J, Rode C, Bloch C . Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res. 1994; 54(12):3253-9. View

20.

Dole M, Jasty R, Cooper M, Thompson C, Nunez G, Castle V . Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res. 1995; 55(12):2576-82. View